Get a fresh start.
Add this topic to your myFT Digest for news straight to your inbox
Vital point on planet’s surface races at unprecedented speed across Arctic
The next test for psilocybin will be to treat depression resistant to existing drugs
Prediction should be possible but the challenge is to transform data into a real-world risk assessment
Swiss start-up ClearSpace to remove ESA’s rocket from orbit
Seven member states to invest in the project which is set to run until 2031
Latest treatments with price tags as high as $2m require new financing models
Margaret Hamburg on the intersection of science and responsibility
Mini-organs grown from human stem cells can test drug effectiveness
Industry cluster aims to get inventions commercialised at home rather than in US
Single treatment using advanced microsurgery can cure condition for life
‘Neural laces’ linking the brain to computers offer new scope for treatments
Replacement skin, livers and bladders on horizon
Biotechs race to serve patients stuck on waiting lists for organs
Rapid advances in technology from bioelectronics to gene therapy offer new ways to treat many illnesses. But medical breakthroughs bring with them new questions of pricing, access and scientific responsibility
Statistics often come from academics sponsored by hygiene businesses but fail a sniff test
Call for inquiry into pace of improvement amid statistical inconsistencies
Biotech’s shares fluctuate as it tries to win over sceptics of aducanumab
Many people feel uneasy about confining wild animals, but the benefits may outweigh the misgivings
Low-power artificial neuron chip can co-ordinate heartbeats with breathing
John Thornhill selects his must-read titles
The earth’s vulnerabilities could interact with each other in unpredictable ways
Ex-minister David Willetts says any new government must be bold in backing R&D
Technology, economics and the law must be enlisted to stop poaching
Applications include period-trackers and screening for cancer
Bulk purchasing guarantees help overcome manufacturers’ reluctance
